RELMADA THERAPEUTICS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
NV
Business Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, FL, 33134
Mailing Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, FL, 33134
Phone
646 876 3459
Fiscal Year End
1231
EIN
455401931
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| DEF 14A Definitive proxy statement | April 17, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | April 3, 2026 | View on SEC |
| 8-K Current report of material events | March 20, 2026 | View on SEC |
| 10-K Annual financial report | March 19, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 12, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 6, 2026 | View on SEC |
| 424B5 Prospectus supplement | January 30, 2026 | View on SEC |
Annual Reports
10-K
March 19, 2026
- Successful strategic pivot to new drug candidates, NDV-01 for bladder cancer and sepranolone for brain disorders.
- NDV-01 showed strong 76% (83% statistical) complete response at 12 months in Phase 2 for bladder cancer, with no new safety issues.
Insider Trading
BUY
2 insiders
2 recent transactions
View Insider Trading Dashboard
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.